Biogen (BIIB) EBIT Margin (2009 - 2026)
Biogen (BIIB) posted quarterly EBIT Margin of 23.56% for Q2 2026, down 2881.0% year-over-year from 0.85% in Q2 2025, and down 106.03% quarter-over-quarter from 11.43% in Q1 2026.
Biogen (BIIB) EBIT Margin (2009 - 2026) Analysis & Trends
Biogen's EBIT Margin history runs 18 years deep, the most recent figure standing at 23.56% for Q2 2026.
- In Q2 2026, EBIT Margin fell 2881.0% year-over-year to 23.56%; the TTM figure through Jun 2026 stood at 15.92% (down 933.0% YoY), while the FY2025 annual figure was 8.57%, down 439.0% from the prior year.
- EBIT Margin for Q2 2026 stood at 23.56%, down from 11.43% in the prior quarter.
- The five-year high for EBIT Margin was 35.94% in Q3 2022, with the low at 31.65% in Q3 2023.
- The 5-year median for EBIT Margin is 4.0% (2024), against an average of 0.63%.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin tumbled 6759 bps in 2023, then jumped 2404 bps in 2024.
- Biogen's EBIT Margin stood at 17.29% in 2022, then tumbled by 69 bps to 5.35% in 2023, then slumped by 322 bps to 11.9% in 2024, then sank by 103 bps to 24.19% in 2025, then rose by 3 bps to 23.56% in 2026.
- Business Quant data shows BIIB's EBIT Margin at 23.56% in Q2 2026, 11.43% in Q1 2026, and 24.19% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 469.65 Bn | 463.08 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 258.06 Bn | 253.16 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 236.35 Bn | 222.36 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 5.72% |
| 10 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -23.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.56% |
| Mar 31, 2026 | -11.43% |
| Dec 31, 2025 | -24.19% |
| Sep 30, 2025 | -4.62% |
| Jun 30, 2025 | 5.25% |
| Mar 31, 2025 | -13.09% |
| Dec 31, 2024 | -11.90% |
| Sep 30, 2024 | -7.61% |
| Jun 30, 2024 | 6.19% |
| Mar 31, 2024 | -3.38% |
| Dec 31, 2023 | 5.35% |
| Sep 30, 2023 | -31.65% |
| Jun 30, 2023 | 4.70% |
| Mar 31, 2023 | -9.11% |
| Dec 31, 2022 | 17.29% |
| Sep 30, 2022 | 35.94% |
| Jun 30, 2022 | 30.34% |
| Mar 31, 2022 | 24.12% |
| Dec 31, 2021 | 21.48% |
| Sep 30, 2021 | 28.57% |